The DOI matches its Crossref record.
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Abstract
Background Human myeloproliferative disorders form a range of clonal haematological malignant diseases, the main members of which are polycythaemia vera, essential thrombocythaemia, and idiopathic myelofibrosis. The molecular pathogenesis of these disorders is unknown, but tyrosine kinases have been implicated in several related disorders. We investigated the role of the cytoplasmic tyrosine kinase JAK2 in patients with a myeloproliferative disorder. Methods We obtained DNA samples from patients with polycythaemia vera, essential thrombocythaemia, or idiopathic myelofibrosis. The coding exons of JAK2 were bidirectionally sequenced from peripheral-blood granulocytes, T cells, or both. Allele-specific PCR, molecular cytogenetic studies, microsatellite PCR, Affymetrix single nucleotide polymorphism array analyses, and colony assays were undertaken on subgroups of patients. Findings A single point mutation (Val617Phe) was identified in JAK2 in 71 (97%) of 73 patients with polycythaemia vera, 29 (57%) of 51 with essential thrombocythaemia, and eight (50%) of 16 with idiopathic myelofibrosis. The mutation is acquired, is present in a variable proportion of granulocytes, alters a highly conserved valine present in the negative regulatory JH2 domain, and is predicted to dysregulate kinase activity. It was heterozygous in most patients, homozygous in a subset as a result of mitotic recombination, and arose in a multipotent progenitor capable of giving rise to erythroid and myeloid cel…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the JAK2 gain-of-function mutation (V617F) has been suggested to play a prominent role in MPNs (Baxter et al., 2005; Levine et al., 2005), being present in in ∼95% of PV, 50% to 60% of ET, and ∼50% of all PMF patients and associated with increased risk of mortality and splenomegaly”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Baxter et al., 2005
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 36
- Spivak, 2003, Chronic myeloproliferative disorders, Hematology (Am Soc Hematol Educ Program), 200, 10.1182/asheducation-2003.1.200 · DOI
- Adamson, 1976, Polycythemia vera: stem-cell and probable clonal origin of the disease, N Engl J Med, 295, 913, 10.1056/NEJM197610212951702 · DOI
- Fialkow, 1981, Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell, Blood, 58, 916, 10.1182/blood.V58.5.916.916 · DOI
- Green, 2004, Management of the myeloproliferative disorders: distinguishing data from dogma, Hematol J, 5, S126, 10.1038/sj.thj.6200438 · DOI
- Skoda, 2004, Chronic myeloproliferative disorders: molecular markers and pathogenesis, Hematol J, 5, S122, 10.1038/sj.thj.6200437 · DOI
- Prchal, 1974, Letter: bone marrow responses in polycythemia vera, N Engl J Med, 290, 1382, 10.1056/NEJM197406132902419 · DOI
- Dai, 1992, Polycythemia vera II: hypersensitivity of bone marrow erythroid, granulocyte-macrophage and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony stimulating factor, Blood, 80, 891, 10.1182/blood.V80.4.891.891 · DOI
- Li, 1994, Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF, Br J Haematol, 87, 471, 10.1111/j.1365-2141.1994.tb08300.x · DOI
- Kobayashi, 1993, Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3, Br J Haematol, 83, 539, 10.1111/j.1365-2141.1993.tb04688.x · DOI
- Axelrad, 2000, Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia, Blood, 96, 3310, 10.1182/blood.V96.10.3310 · DOI
- Hinshelwood, 1997, Pathogenesis of polycythaemia vera, Blood Rev, 11, 224, 10.1016/S0268-960X(97)90021-7 · DOI
- Deininger, 2000, The molecular biology of chronic myeloid leukemia, Blood, 96, 3343, 10.1182/blood.V96.10.3343 · DOI
- Reilly, 2003, Receptor tyrosine kinases in normal and malignant haematopoiesis, Blood Rev, 17, 241, 10.1016/S0268-960X(03)00024-9 · DOI
- Wadleigh, 2005, After chronic myelogenous leukaemia: tyrosine kinase inhibitors in other hematologic malignancies, Blood, 105, 22, 10.1182/blood-2003-11-3896 · DOI
- Komura, 2003, Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression, Exp Hematol, 31, 622, 10.1016/S0301-472X(03)00085-7 · DOI
- Ugo, 2004, Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera, Exp Hematol, 32, 179, 10.1016/j.exphem.2003.11.003 · DOI
- Landolfi, 2004, Efficacy and safety of low-dose aspirin in polycythemia vera, N Engl J Med, 350, 114, 10.1056/NEJMoa035572 · DOI
- Pearson, 2001, Evaluation of diagnostic criteria in polycythemia vera, Semin Hematol, 38, 21, 10.1016/S0037-1963(01)90136-2 · DOI
- Murphy, 1997, Experience of the polycythemia vera study group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment, Semin Hematol, 34, 29
- Barosi, 1999, The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia, Br J Haematol, 104, 730, 10.1046/j.1365-2141.1999.01262.x · DOI
- Bench, 2000, Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes, Oncogene, 19, 3902, 10.1038/sj.onc.1203728 · DOI
- Dameshek, 1951, Some speculations on the myeloproliferative syndromes, Blood, 6, 372, 10.1182/blood.V6.4.372.372 · DOI
- Griesshammer, 2004, PRV-1 mRNA expression discriminates two types of essential thrombocythemia, Ann Hematol, 83, 364, 10.1007/s00277-004-0864-9 · DOI
- Kralovics, 2005, Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders, Blood Rev, 19, 1, 10.1016/j.blre.2004.02.002 · DOI
- Harrison, 2003, Essential thrombocythemia, Hematol Oncol Clin North Am, 17, 1175, 10.1016/S0889-8588(03)00082-0 · DOI
- Kralovics, 2002, Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera, Exp Hematol, 30, 229, 10.1016/S0301-472X(01)00789-5 · DOI
- Peeters, 1997, Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia, Blood, 90, 2535, 10.1182/blood.V90.7.2535 · DOI
- Lacronique, 1997, A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia, Science, 278, 1309, 10.1126/science.278.5341.1309 · DOI
- Saharinen, 2000, Regulation of the Jak2 tyrosine kinase by its pseudokinase domain, Mol Cell Biol, 20, 3387, 10.1128/MCB.20.10.3387-3395.2000 · DOI
- Saharinen, 2002, The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction, J Biol Chem, 277, 47954, 10.1074/jbc.M205156200 · DOI
- Lindauer, 2001, Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation, Protein Eng, 14, 27, 10.1093/protein/14.1.27 · DOI
- Luo, 1997, Mutation in the Jak kinase JH2 domain hyperactivates drosophila and mammalian Jak-Stat pathways, Mol Cell Biol, 17, 1562, 10.1128/MCB.17.3.1562 · DOI
- Silva, 1998, Expression of Bcl-x in erythroid precursors from patients with polycythemia vera, N Engl J Med, 338, 564, 10.1056/NEJM199802263380902 · DOI
- Klippel, 2003, Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis, Blood, 102, 3569, 10.1182/blood-2003-03-0919 · DOI
- Moliterno, 1998, Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera, N Engl J Med, 338, 572, 10.1056/NEJM199802263380903 · DOI
- Gesbert, 2000, Bcr/Abl activates transcription of the Bcl-X gene through STAT5, Blood, 96, 2269, 10.1182/blood.V96.6.2269 · DOI
Cited by
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., Avezov, E., Li, J., Kollmann, K., Kent, D. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1312542 · Cited by 1,756
Self-citationMechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Biology and significance of the JAK/STAT signalling pathways
Kiu, H., & Nicholson, S. E. (2012) · Growth Factors · doi:10.3109/08977194.2012.660936 · Cited by 470
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
Arranz, L., Sánchez-Aguilera, A., Martín-Pérez, D., Isern, J., Langa, X., Tzankov, A., Lundberg, P., Muntión, S., Tzeng, Y.-S., Lai, D.-M., et al. (2014) · Nature · doi:10.1038/nature13383 · Cited by 444
Kinase mutations in human disease: interpreting genotype–phenotype relationships
Lahiry, P., Torkamani, A., Schork, N. J., & Hegele, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2707 · Cited by 420
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“Bone marrow fibrosis is a shared feature of all MPNs, but is the defining histopathological feature of PMF, a major diagnostic criterion (Zahr et al., 2016), and has been associated with poor outcomes (Kuter et al., 2007; Byrne et al., 2018).”
BackgroundInfluentialHinds, D. A., Barnholt, K. E., Mesa, R. A., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., Francke, U., Tung, J. Y., Nguyen, H. (., et al. (2016) · Blood · doi:10.1182/blood-2015-06-652941 · Cited by 267
Hultcrantz, M., Björkholm, M., Dickman, P. W., Landgren, O., Derolf, Å. R., Kristinsson, S. Y., & Andersson, T. M. L. (2018) · Annals of Internal Medicine · doi:10.7326/m17-0028 · Cited by 268
McConnell, M. J., Moran, J. V., Abyzov, A., Akbarian, S., Bae, T., Cortes-Ciriano, I., Erwin, J. A., Fasching, L., Flasch, D. A., Freed, D., et al. (2017) · Science · doi:10.1126/science.aal1641 · Cited by 262
Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2 V617F Mice
Wang, W., Liu, W., Fidler, T., Wang, Y., Tang, Y., Woods, B., Welch, C., Cai, B., Silvestre-Roig, C., Ai, D., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313283 · Cited by 262
Hematopoietic cytokine receptor signaling
Baker, S. J., Rane, S. G., & Reddy, E. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210757 · Cited by 256
Ba/F3 cells and their use in kinase drug discovery
Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a25f · Cited by 240
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia
Ramos, P., Casu, C., Gardenghi, S., Breda, L., Crielaard, B. J., Guy, E., Marongiu, M. F., Gupta, R., Levine, R. L., Abdel-Wahab, O., et al. (2013) · Nature Medicine · doi:10.1038/nm.3126 · Cited by 227
Van Egeren, D., Escabi, J., Nguyen, M., Liu, S., Reilly, C. R., Patel, S., Kamaz, B., Kalyva, M., DeAngelo, D. J., Galinsky, I., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.02.001 · Cited by 206
The HIF pathway and erythrocytosis
Lee, F. S., & Percy, M. J. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130321 · Cited by 177
Scott, L. M., Campbell, P. J., Baxter, E. J., Todd, T., Stephens, P., Edkins, S., Wooster, R., Stratton, M. R., Futreal, P. A., & Green, A. R. (2005) · Blood · doi:10.1182/blood-2005-05-2087 · Cited by 158
Self-citationMinihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676742 · Cited by 148
Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications
Pourcelot, E., Trocme, C., Mondet, J., Bailly, S., Toussaint, B., & Mossuz, P. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.01.006 · Cited by 132
Janus kinase deregulation in leukemia and lymphoma
Chen, E., Staudt, L. M., & Green, A. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.017 · Cited by 123
Self-citationNeural regulation of bone and bone marrow
Maryanovich, M., Takeishi, S., & Frenette, P. S. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031344 · Cited by 114
Fetal lung and placental methylation is associated with in utero nicotine exposure
Chhabra, D., Sharma, S., Kho, A. T., Gaedigk, R., Vyhlidal, C. A., Leeder, J. S., Morrow, J., Carey, V. J., Weiss, S. T., Tantisira, K. G., et al. (2014) · Epigenetics · doi:10.4161/15592294.2014.971593 · Cited by 102
Canté-Barrett, K., Spijkers-Hagelstein, J. A. P., Buijs-Gladdines, J. G. C. A. M., Uitdehaag, J. C. M., Smits, W. K., van der Zwet, J., Buijsman, R. C., Zaman, G. J. R., Pieters, R., & Meijerink, J. P. P. (2016) · Leukemia · doi:10.1038/leu.2016.83 · Cited by 94
Al-Sheikh, M., Moradkhani, K., Lopez, M., Wajcman, H., & Préhu, C. (2008) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.017 · Cited by 50
Metadata
- Authors
- Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., Scott, M. A., Erber, W. N., & Green, A. R.
- Affiliations
- University of Cambridge (GB)
- Addenbrooke's Hospital (GB)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 365
- Issue
- 9464
- Pages
- 1054-1061
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2144664431
- Cited by
- 3,548
- References
- 0
- Citations by year
- 2026: 66 · 2025: 77 · 2024: 98 · 2023: 126 · 2022: 130 · 2021: 141 · 2020: 145 · 2019: 135 · 2018: 126 · 2017: 158 · 2016: 176 · 2015: 204 · 2014: 193 · 2013: 201 · 2012: 210
- FWCI
- 109.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (088340)
- Topics
- Health Sciences › Medicine › Hematology › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- JAK2, myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, primary myelofibrosis, tyrosine kinase, acquired mutations, mitotic recombination, molecular pathogenesis
- MeSH terms
- Chromosomes, Human, Pair 9, Colony-Forming Units Assay, Granulocytes, Hematopoietic Stem Cells, Humans, Myeloproliferative Disorders, Polycythemia Vera, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Thrombocythemia, Essential, Signal Transduction, Polymerase Chain Reaction, Point Mutation, In Situ Hybridization, Fluorescence, Loss of Heterozygosity, Janus Kinase 2, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
